Group items tagged

The Royal Pharmaceutical Society (RPS) and the charity Marie Curie have developed a consultation on 'professional standards for palliative and end of life care for community pharmacy'. The consultation will be open for four weeks for community pharmacists, organisations with a role in community pharmacy or palliative/end of life care, or patients or carers with first-hand experience of palliative and end of life care to share their views until 1st December 2022. Through this consultation, Society aims to that ensure the standards are clear, relevant, current, and fit for purpose from the perspective of the community pharmacy team, the wider health team and patients/carers. "The final standards will be published in 2023 and will help community pharmacies across the UK to self-assess and continuously improve their palliative, end of life and bereavement care," said RPS.

Nurse Palliative Care: Identify the Risk Factors of depression in older population, approach to caring for Older PWH with cardiac, renal or metabolic bone disease

definition of palliative care

definition of palliative care

Boots UK in association with Macmillan Cancer Support and the NHS has launched a Palliative Care Service in its pharmacies to provide easy access to vital medicines and specialist pharmacist advice and support to patients. As part of the new service, Boots has created a list of recommended medicines most used by terminally ill patients. It has committed to maintain stock of these medicines, or formulary, at over 2,000 of its pharmacies with an NHS contract. To further support the launch of the new service, all 4,200 Boots Macmillan Information Pharmacists (BMIP) have received additional training on palliative care, including a range of cancer-related advice and side effects of medication. Marc Donovan, chief pharmacist at Boots said: "Discussing end-of-life care is never easy, but it is very important. At this extremely difficult time for patients and their families and carers, ease of access to medicines and support can make a big difference.

Management of Common Symptoms in Palliative Care is organized by eMedEvents Corporation. Identify assessment measures for common end-of-life symptoms

The Royal Pharmaceutical Society (RPS) has launched a partnership with the charity Marie Curie to develop professional standards in end of life care for community pharmacy. Available for pharmacy teams across the UK, the standards will provide a free, evidence-based framework to help community pharmacies self-assess and continuously improve their end of life and bereavement care for patients and carers. They will enable community pharmacy teams to work together to develop their own practice. RPS is setting up a professional standard steering group which will have community pharmacy experts, experts within the field of palliative and end of life care, lay members, and healthcare professionals who interact with community pharmacy. Elen Jones, director lead for palliative care work at RPS, said: "RPS has a long-term commitment, striving to ensure that people living with life-limiting conditions who are approaching the end of life have timely access to medicines and clinical support from a skilled pharmacy team. "The development of these standards, in partnership with Marie Curie, is a crucial step to support community pharmacy teams to undertake simple quality improvement measures and build upon the care they already provide to this group of patients and carers."

RPS Scotland has partnered with charity organisation Marie Curie for an exhibition at the Scottish Parliament this week to highlight Daffodil Standards and the crucial contribution of community pharmacies to palliative and end-of-life care. The exhibition is being sponsored by Jeremy Balfour MSP. Community pharmacies offer vital assistance by providing guidance on medication adjustments and side effects, RPS Scotland said in a statement. They are easily accessible without the need for an appointment, providing essential support and reassurance to families in times of need. The Daffodil Standards, which is jointly developed by RPS and Marie Curie, drive continuous improvement in end-of-life and bereavement support within community pharmacies, benefiting terminally ill patients, their families, and caregivers. These standards align with the RCGP/Marie Curie guidelines for general practice introduced in 2019. Since its May launch, over 450 pharmacies throughout Great Britain, including more than 30 in Scotland, have implemented these principles, the statement said.

Leading pharmacy group Weldricks has strengthened its commitment to providing the highest quality of care to the communities it serves by implementing the RPS Daffodil Quality Improvement Standards for Community Pharmacy. The Royal Pharmaceutical Society (RPS) on Monday (20 November) announced that Weldricks will soon be rolling out the Daffodil Standards across half its stores in South Yorkshire. Developed in partnership with UK charity Marie Curie, the RPS Daffodil Standards serve as a framework for improving the quality of palliative and end-of-life care provided by community pharmacy teams. Amy Marlin, Superintendent Pharmacist of Weldricks, commented that the implementation of the RPS Daffodil Standards is "another step forward in our journey to provide the highest quality of care to the communities we serve."

A three-year contract has been signed between NHS Education for Scotland (NES) and Pharmaceutical Press, the Royal Pharmaceutical Society's (RPS) knowledge business, to continue the supply of trusted medicines information though MedicinesComplete, to healthcare professionals in Scotland. The renewed investment from NES demonstrates unequivocal confidence in the publisher and highlights Pharmaceutical Press' ongoing commitment to provide practical and evidence-based guidance, supporting those who prescribe, dispense, and administer medicines. Essential resources include Martindale: The Complete Drug Reference, Palliative Care formulary, Stockley's Drug Interactions and Critical Illness. Relied on by healthcare professionals globally for use in everyday practice, clear and concise guidance through MedicinesComplete supports confident decision-making at the point of care.

Holistic Approach to Primary Care webinar is organized by eMedEvents and mainly focuses on the current developments in primary care. Topics include infectious diseases, palliative care, surgical procedures and medical practice.

Levomepromazine 25mg/1ml solution for injection will remain unavailable until the week commencing March 7,2022, Department of Health and Social Care (DHSC) said in an update. While alternative medicines for use in palliative care remain available in ample supply to support an uplift in demand, the date supply resumption of Levomepromazine is yet to be confirmed. The DHSC has sent a copy of this medicine supply notification to all pharmacy NHS email addresses. It further informed primary care providers that prescription validation has been temporarily implemented at wholesaler level.

The Department of Health and Social Care (DHSC) has issued a medicine supply notification for Sulfasalazine 250mg in 5ml oral suspension sugar free; Pilocarpine hydrochloride 4% eye drops; Fluticasone 50microgram / Salmeterol 25microgam (Combisal) pressurised metered dose inhaler (pMDI); and Dalteparin (Fragmin) 10,000units/1mL solution for injection ampoule on Wednesday (21 December). "Sulfasalazine 250mg/5ml oral suspension sugar free is out of stock from w/c 19th December until early June 2023. Sulfasalazine 500mg non-enteric coated tablets remain available "IPS Pharma, Nova Labs, and Rokshaw have currently confirmed they can manufacturer sulfasalazine 250mg/5ml oral suspension," said DHSC. Pilocarpine 4% eye drops are out of stock until w/c 26th December 2022. Alternative strengths of pilocarpine (1% and 2%) eye drops remain available and will be able to support increased demand. Specials of pilocarpine 4% preservative free eye drops are available if the licensed alternatives are not suitable. For off-label use of the 4% drops in the treatment of xerostomia (dry mouth) in palliative care, pilocarpine 5mg tablets are available and are licensed for this indication.